Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents mixed signals. Basic financial performance shows growth in test volumes and revenue, but increased operating expenses and a significant net loss raise concerns. Positive developments include UnitedHealthcare coverage and increased Medicare mix, yet regulatory risks and unclear timelines for Medicare coverage finalization temper optimism. The Q&A session reveals cautious management and uncertainties, particularly regarding Medicare efforts and financial sustainability. Overall, the neutral sentiment reflects balanced positive and negative factors, suggesting limited short-term stock movement.
Key Financial Performance
EsoGuard test volume 3,664 tests in Q4 2025, representing a 29% increase from Q3 2025. The increase is attributed to exceeding the target range of 2,500 to 3,000 tests per quarter.
Revenue $1.5 million in Q4 2025, a 24% increase from Q3 2025. The growth is linked to higher test volumes and ongoing commercial efforts.
Cash at year-end $34.7 million as of December 31, 2025. The average burn rate for 2025 was $11.1 million per quarter, with a higher Q4 burn due to investments in sales and market access staffing.
Operating expenses $48.7 million in 2025, up from $44.3 million in 2024, a $4.4 million increase. This rise is due to higher sales personnel costs, market access staff expenses, and annual compensation expenditures.
Non-GAAP net loss $44 million in 2025, compared to $40 million in 2024. The increase is attributed to higher operating expenses, including personnel and compensation costs.
Non-GAAP net loss per share $0.43 for 2025, an improvement compared to $0.10 in Q4 2025. This reflects better cost management despite increased expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EsoGuard test volume: Test volume in Q4 was 3,664, exceeding the target range of 2,500-3,000 tests per quarter, representing a 29% increase from Q3 2025.
EsoGuard and EsoCheck real-world data: Positive data from a study of nearly 12,000 at-risk patients confirmed excellent technical performance, rapid cell collection times, and 100% safety, setting a high standard for esophageal precancer screening tools.
VA contract for EsoGuard: Awarded a U.S. Department of Veteran Affairs contract under the Federal Supply Schedule, enabling access to 170 medical centers and 9 million veterans annually.
Commercial payer engagement: Progress with UnitedHealthcare, Cigna, and Anthem for potential in-network coverage of EsoGuard, leveraging policies related to endoscopy.
Reimbursement progress: Awaiting Medicare draft LCD publication, with positive signs from prior engagements and CAC meeting outcomes.
EHR integration: Initiatives underway to integrate EsoGuard into electronic health records (EHR) systems to streamline test ordering and result delivery.
Focus on VA and Medicare: Reallocating resources to target VA and Medicare opportunities, with a senior leader appointed as national director for VA engagements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare Coverage Delays: The company is experiencing delays in obtaining Medicare coverage for its EsoGuard test, which is critical for revenue growth and market penetration. This delay is attributed to logistical issues and impacts the ability to engage with health systems effectively.
Commercial Payer Challenges: The company faces challenges in securing in-network coverage with commercial payers. While there is progress with some payers like UnitedHealthcare, others require additional cost-effectiveness data, which is still being developed.
VA System Resource Limitations: The VA system, while a significant opportunity, has resource limitations, particularly with EGD procedures. This could impact the adoption and implementation of EsoGuard testing within the VA centers.
Revenue Recognition Constraints: Revenue recognition is constrained due to the transitional stages of the reimbursement process. The majority of claims are recognized only upon collection, which delays revenue realization and impacts financial reporting.
Cash Burn and Operational Costs: The company has a high cash burn rate, averaging $11.1 million per quarter, with additional investments in sales and market access staff. This raises concerns about financial sustainability without significant revenue growth.
Regulatory and Reimbursement Risks: The company is heavily reliant on regulatory approvals and reimbursement policies, which are uncertain and could significantly impact its financial and operational performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Medicare Coverage: The company is awaiting the publication of the draft LCD for Medicare coverage of EsoGuard. They are confident this is imminent and expect a 45-day public comment period followed by a final LCD publication. Once finalized, Lucid will be eligible for payments on Medicare claims dating back one year.
Commercial Payer Engagement: Lucid is actively engaging with commercial payers, including UnitedHealthcare, Cigna, and Anthem, to secure in-network coverage for EsoGuard. They are also working with laboratory benefit management groups and integrated delivery networks to expand coverage.
VA Contract and Expansion: Lucid has secured a contract with the U.S. Department of Veteran Affairs (VA) for EsoGuard at the Medicare rate. They are engaging with individual VA centers to drive test adoption and revenue. The VA system serves approximately 9 million veterans annually, a clinically relevant population for EsoGuard.
EHR Integration: Lucid is investing in electronic health record (EHR) integration to facilitate test ordering and result delivery. They plan to expand these efforts as test volume increases.
Revenue Recognition and Future Growth: Pending Medicare approval impacts 40%-50% of the addressable patient population. Lucid expects significant revenue growth once Medicare coverage is secured. They are also focusing on converting lessons learned into revenue through VA and Medicare opportunities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What contributed to the sequential increase in testing volumes, and is this a new run rate?
A:The 800 increase in testing volumes is not directly attributable to the VA as it is too early for that. The increase is due to improved team productivity and transitioning efforts towards Medicare and the VA. Management believes this could represent a new run rate.
Q:What is the status of health plan coverage, particularly with UnitedHealthcare?
A:UnitedHealthcare has included EsoGuard as an appropriate indication for an EGD within their endoscopy guidelines, which management interprets as de facto coverage. The team has initiated the credentialing process to become an in-network provider and plans to enter contracting discussions shortly.
Q:What are the efforts to reallocate resources to Medicare lives, and when can productivity be measured?
A:The team is transitioning from event-based testing to engaging with physicians and health systems to increase Medicare volume. While maintaining volume and revenue, the shift is progressing well. Management does not expect to report individual rep productivity until next year.
Q:What is the Medicare mix over the last 2-3 quarters, and how does it relate to billable claims?
A:The Medicare mix increased from 10-12% in prior quarters to 16% in the fourth quarter, reflecting a 28% sequential increase. The $9 million in billable claims is based on the Medicare rate and reflects the early stages of transitioning efforts.
Q:What is the significance of the LBM positive coverage policy, and how does it impact volume and revenue?
A:The LBM positive coverage policy aligns with existing guidelines and is a step towards broader coverage. While it won't immediately translate to volume and revenue, it allows for contracting discussions and targeting specific geographic areas.
Q:What is the geographic alignment of sales reps with VA facilities?
A:Sales reps engage with local VA centers to identify physician champions, and a national team executes the launch. Many VA centers are linked with academic medical centers, providing additional opportunities for engagement.
Q:What is the total addressable market for the VA, and what is the expected testing volume run rate for 2026?
A:The VA serves 9 million lives, with 20-25% of the population recommended for testing, representing a couple of million patients. Management aims to sustain higher testing volumes as VA and Medicare efforts progress.
Q:Why is the company cautious about increasing sales efforts for Medicare despite the 1-year lookback period?
A:The company is cautious due to the current capital markets environment and the need to manage operating expenses. They plan to accelerate sales efforts once Medicare coverage is finalized.
Q:What is the estimated amount of Medicare testing that can be billed retroactively?
A:The estimated amount of Medicare testing that can be billed retroactively is a couple of million dollars, which changes daily as the final policy is awaited.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the exact timing of Medicare coverage finalization and the specific impact of the LBM positive coverage policy on volume and revenue. Additionally, they did not provide a clear timeline for when individual rep productivity metrics would be reported.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Blue Cross
EGD
EHR integration
Epic
EsoGuard EsoCheck
FSS
LBM
LBMs
LCD notice
Medicare VA
PO
UnitedHealthcare
VA Medicare
VA center
VA contract
VA population
VA side
ability health
cell collection
center country
champion
contrast sponge
cost effectiveness
coverage front
demand
depth
identification
minute
network coverage
pathway
patient world
physician adoption
procedure
side Medicare
side VA
way EHR
win
world experience
LUCD Transcript
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
Unknown5-14
Despite the 25% revenue growth and improved margins, the ongoing net loss and negative cash flow indicate financial challenges. The lack of discussion on strategic initiatives and operational updates limits visibility into future growth. However, the financial improvements and potential Medicare coverage provide some optimism, balancing the sentiment to neutral.
Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript
Unknown3-26
The earnings call summary presents mixed signals. Basic financial performance shows growth in test volumes and revenue, but increased operating expenses and a significant net loss raise concerns. Positive developments include UnitedHealthcare coverage and increased Medicare mix, yet regulatory risks and unclear timelines for Medicare coverage finalization temper optimism. The Q&A session reveals cautious management and uncertainties, particularly regarding Medicare efforts and financial sustainability. Overall, the neutral sentiment reflects balanced positive and negative factors, suggesting limited short-term stock movement.
Lucid Diagnostics Inc. (LUCD) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call highlights strong financial management with controlled expenses and a positive cash position, despite a recent public offering. The strategic focus on Medicare coverage and commercialization of EsoGuard, paired with promising partnerships and expansion plans, is positive. However, uncertainties in the timeline for Medicare coverage and the need for more commercial payer support slightly temper the outlook. Overall, the sentiment leans positive due to the potential revenue growth and strategic partnerships, but the absence of a clear timeline for Medicare approval keeps it from being strongly positive.
Lucid Diagnostics Inc. (LUCD) Investor Conference Call (Transcript)
Neutral9-8
LUCD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
